Glucotrack Announces Data From Feasibility Study For Implantable Continuous Glucose Monitor
Portfolio Pulse from Benzinga Newsdesk
Glucotrack, Inc. (NASDAQ:GCTK) has announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The study confirmed that the CGM sensor design could reliably report glucose measurements for two years post-implant. The company is now preparing for long-term animal studies.
July 25, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Glucotrack's positive results from the feasibility study for its implantable continuous glucose monitor technology could potentially boost its stock in the short term.
The positive results from the feasibility study indicate that Glucotrack's implantable continuous glucose monitor technology is reliable and could be a game-changer in the diabetes management market. This could potentially attract more investors, leading to a rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100